Lv4
480 积分 2021-03-01 加入
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
1个月前
已完结
HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade
2个月前
已完结
Antibody-drug conjugates in oncology: A spotlight on overcoming resistance
2个月前
已完结
HER2-targeted therapies — a role beyond breast cancer
2个月前
已完结
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
2个月前
已完结
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
4个月前
已完结
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
5个月前
已完结
Mezigdomide Data Show CELMoD Potential
5个月前
已完结
ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
6个月前
已完结
Pemetrexed in first-line treatment of non-small cell lung cancer
7个月前
已完结
皖公网安备34019202002308
